RiethPharma

RiethPharma has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €68,481 and a net result of €9,947. Equity is shrinking by ~15% per year across the filed fiscal years. Its solvency ranks better than 63% of 12331 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).